2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N3841B
    (Rac)-δ-Viniferin 98.89%
    (Rac)-δ-Viniferin is a racemate of δ-Viniferin (HY-N3841A), an isomer of ε-Viniferin (HY-N3841). ε-Viniferin (epsilon-Viniferin), the dimer of Resveratrol, displays a potent inhibitory effect for all the CYP activities, with Ki values from 0.5-20 μM. ε-Viniferin possesses potent antioxidant, anti-inflammatory, anti-diabetic, and anti-neurodegenerative capacity.
    (Rac)-δ-Viniferin
  • HY-N7085R
    Citropten (Standard) 487-06-9 98.67%
    Citropten (Standard) is the analytical standard of Citropten. This product is intended for research and analytical applications. Citropten (5, 7-dimethoxycoumarin) is one of the coumarin derivatives. Citropten is an effective oral anticancer agent. Citropten has anti-proliferative activity against A2058 and B16 melanoma cells. Citropten exerts anti-inflammatory effects through the NFκB and MAPK signaling pathways. Citropten acts as an antidepressant through heat shock protein-70, monoamine oxidase-A and inhibition of apoptosis .
    Citropten (Standard)
  • HY-N7117R
    1,4-Cineole (Standard) 470-67-7
    1,4-Cineole (Standard) is the analytical standard of 1,4-Cineole (HY-N7117). 1,4-Cineole is an oxygenated monoterpene found in eucalyptus oil. 1,4-Cineole is a hTRPM8 and hTRPA1 agonist. 1,4-Cineole can increase intracellular Ca2+ concentration. 1,4-Cineole exhibits anti-anxiety and anti-depression effects. 1,4-Cineole can be used for the research of neurological disease, such as depression .
    1,4-Cineole (Standard)
  • HY-N7560R
    Safranal (Standard) 116-26-7 99.89%
    Safranal (Standard) is an analytical standard for Safranal. This product is intended for research and analytical applications. Safranal is the main component of saffron (Crocus sativus), is orally active, and is the source of the spice's unique aroma. Safranal has neuroprotective and anti-inflammatory effects and has research potential for Parkinson's disease.
    Safranal (Standard)
  • HY-N7699B
    D-Tetramannuronic acid 149511-34-2 98.0%
    D-Tetramannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Tetramannuronic acid can be used for the research of pain and vascular dementia.
    D-Tetramannuronic acid
  • HY-P0041A
    F992 TFA 98.19%
    F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue.
    F992 TFA
  • HY-P1012A
    [Sar9,Met(O2)11]-Substance P TFA 2828433-10-7 98.58%
    [Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK1 receptor selective agonist.
    [Sar9,Met(O2)11]-Substance P TFA
  • HY-P10148
    N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) 155709-24-3 98.03%
    N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) is a selective agonist of neuropeptide Y Y2 receptor. N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) attenuates cardiac vagal action in anaesthetised rats.
    N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36)
  • HY-P10358
    TAT-CBD3A6K 1505463-57-9 98.26%
    TAT-CBD3A6K, is a modified TAT-CBD3 peptide. TAT-CBD3A6K reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function.
    TAT-CBD3A6K
  • HY-P10397
    YHIEPV 2243939-21-9 99.85%
    YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is a potent and orally active peptide. YHIEPV shows anxiolytic effects. YHIEPV increases leptin sensitivity to exert its anti-obesity effects.
    YHIEPV
  • HY-P1051A
    β-Amyloid (12-28) TFA 99.80%
    β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research.
    β-Amyloid (12-28) TFA
  • HY-P10818
    Polyglutamine binding peptide 1 274914-75-9 99.52%
    Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture.
    Polyglutamine binding peptide 1
  • HY-P10824
    RI-OR2-TAT 1430219-69-4 98%
    RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus.
    RI-OR2-TAT
  • HY-P10998
    Tet1 peptide 270919-17-0 98%
    Tet1 peptide is a peptide that specifically binds to neurons. Tet1 peptide binds to GT1B ganglioside and trisialoganglioside clostridial toxin receptor on the surface of neuronal cells, and can be used in peptide conjugation and drug delivery research.
    Tet1 peptide
  • HY-P11094
    Tet1-Cys peptide 1048681-88-4 99.13%
    Tet1-Cys peptide is a peptide with the sequence HLNILSTLWKYRC. Tet1 (HLNILSTLWKYR) (HY-P10998) can specifically bind to the neuronal ganglioside receptor GT1b, possessing neuronal targeting capabilities. The Tet1-Cys peptide sequence has an added Cys, which can be used for drug conjugation for research on drug delivery.
    Tet1-Cys peptide
  • HY-P11117
    TAT-EE3 2899218-49-4 99.89%
    TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke.
    TAT-EE3
  • HY-P11480
    TrkA/NGF-IN-1 3105660-96-3 98.22%
    TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC50: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model.
    TrkA/NGF-IN-1
  • HY-P11501
    AAKLVFF 1038400-67-7 99.83%
    AAKLVFF is an oligopeptide capable of self-assembling into nanotubes. AAKLVFF can be derived from the core section of β-amyloid. AAKLVFF becomes the first methanol compatible LC alignment medium for residual dipolar coupling measurement.
    AAKLVFF
  • HY-P11632
    YLDLAPL 98.39%
    YLDLAPL is a sleep-enhancing peptide that can be isolated from truffle albumin hydrolysate. YLDLAPL exhibits sleep-promoting effects via regulation of lysosomal autophagy, neurological activity, tyrosine metabolism, and fatty acid elongation.
    YLDLAPL
  • HY-P11633
    YLRPEGDW 99.43%
    YLRPEGDW is an orally active sleep-promoting peptide. YLRPEGDW upregulates Autophagy-related genes, increase Autophagy activity. YLRPEGDW could improve Caffeine-induced sleep reduction.
    YLRPEGDW
Cat. No. Product Name / Synonyms Application Reactivity